Gabor I Keitner1, Michael A Posternak, Christine E Ryan. 1. Department of Psychiatry and Human Behavior, Brown University School of Medicine, Rhode Island Hospital, 593 Eddy St., Providence, RI 02903, USA. gkeitner@lifespan.org
Abstract
OBJECTIVE: To evaluate the generalizability of the results of antidepressant efficacy trials by determining how many subjects with DSM-IV major depressive disorder who apply for entry into such trials are ultimately enrolled. METHOD: The screening results of 378 subjects who inquired about participating in 1 of 2 separate antidepressant efficacy trials performed at Rhode Island Hospital between 1997 and 2002 were reviewed. The number of subjects who enrolled, as well as the reasons for exclusion of those who did not meet eligibility requirements, were determined. RESULTS: Of the 378 inquiries, 186 subjects expressed interest and received a current major depressive disorder diagnosis. From this sample, 27 (14.5%) were ultimately enrolled in 1 of the 2 antidepressant trials. The most common reasons for exclusion were bipolar disorder (17.2%), drug or alcohol abuse (15.6%), mild depression (14.0%), medical contraindication (12.9%), and the use of prohibited psychotropic medications (12.4%). CONCLUSION: The majority of subjects with major depressive disorder who apply to participate in an antidepressant efficacy trial do not meet eligibility requirements. When prescribing antidepressants, clinicians should bear in mind that the results of these trials may only be directly applicable to a small subset of patients treated in clinical practice.
OBJECTIVE: To evaluate the generalizability of the results of antidepressant efficacy trials by determining how many subjects with DSM-IV major depressive disorder who apply for entry into such trials are ultimately enrolled. METHOD: The screening results of 378 subjects who inquired about participating in 1 of 2 separate antidepressant efficacy trials performed at Rhode Island Hospital between 1997 and 2002 were reviewed. The number of subjects who enrolled, as well as the reasons for exclusion of those who did not meet eligibility requirements, were determined. RESULTS: Of the 378 inquiries, 186 subjects expressed interest and received a current major depressive disorder diagnosis. From this sample, 27 (14.5%) were ultimately enrolled in 1 of the 2 antidepressant trials. The most common reasons for exclusion were bipolar disorder (17.2%), drug or alcohol abuse (15.6%), mild depression (14.0%), medical contraindication (12.9%), and the use of prohibited psychotropic medications (12.4%). CONCLUSION: The majority of subjects with major depressive disorder who apply to participate in an antidepressant efficacy trial do not meet eligibility requirements. When prescribing antidepressants, clinicians should bear in mind that the results of these trials may only be directly applicable to a small subset of patients treated in clinical practice.
Authors: Mark Zimmerman; Matthew Multach; Emily Walsh; Lia K Rosenstein; Douglas Gazarian; Heather L Clark Journal: CNS Drugs Date: 2016-03 Impact factor: 5.749
Authors: W Curt LaFrance; Andrew S Blum; Ivan W Miller; Christine E Ryan; Gabor I Keitner Journal: J Neuropsychiatry Clin Neurosci Date: 2007 Impact factor: 2.198
Authors: Christian A Webb; Zachary D Cohen; Courtney Beard; Marie Forgeard; Andrew D Peckham; Thröstur Björgvinsson Journal: J Consult Clin Psychol Date: 2020-01
Authors: Andrew C Leon; David A Solomon; Chunshan Li; Jess G Fiedorowicz; W H Coryell; Jean Endicott; Martin B Keller Journal: J Clin Psychiatry Date: 2011-05 Impact factor: 4.384
Authors: W C LaFrance; G I Keitner; G D Papandonatos; A S Blum; J T Machan; C E Ryan; I W Miller Journal: Neurology Date: 2010-08-25 Impact factor: 9.910
Authors: Sana M Al-Khatib; Anne Hellkamp; Gust H Bardy; Stephen Hammill; W Jackson Hall; Daniel B Mark; Kevin J Anstrom; Jeptha Curtis; Hussein Al-Khalidi; Lesley H Curtis; Paul Heidenreich; Eric D Peterson; Gillian Sanders; Nancy Clapp-Channing; Kerry L Lee; Arthur J Moss Journal: JAMA Date: 2013-01-02 Impact factor: 56.272
Authors: Koen Demyttenaere; Anne Verhaeghen; Nicolas Dantchev; Luigi Grassi; Angel L Montejo; David G S Perahia; Deborah Quail; Catherine Reed; Andre Tylee; Michael Bauer Journal: Prim Care Companion J Clin Psychiatry Date: 2009
Authors: Mark Zimmerman; Carolina Guzman Holst; Heather L Clark; Matthew Multach; Emily Walsh; Lia K Rosenstein; Douglas Gazarian Journal: CNS Drugs Date: 2016-12 Impact factor: 5.749
Authors: David E Kemp; Keming Gao; Elizabeth B Fein; Philip K Chan; Carla Conroy; Sarah Obral; Stephen J Ganocy; Joseph R Calabrese Journal: Bipolar Disord Date: 2012-11 Impact factor: 6.744